News

We are very proud to annouce that our human midbrain organoid technology was selected for the SLAS 2021 New Product…

The article “Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening”…

OrganoTherapeutics is very happy to announce that we have been selected as participants in the Luxembourgish Fit4Start program. The selection…

We are very happy to announce that OrganoTherapeutics has been accepted into the Creative Destruction Lab (CDL) program (https://www.linkedin.com/company/creative-destruction-lab/). We…

Today a new study with the title “Finding new treatment targets in Parkinson’s using a patient-based model of RNA mis-splicing”…

The OrganoTherapeutics team is very excited to announce that we have been accepted in the 2020 cohort of the MassChallenge…

We use human midbrain organoids to investigate if toxins can induce Parkinson`s disease like phenotypes. Additionally, this can be used…

We are very proud to have been selected as finalist in the Start-up Stadium at the Bio International Convention. This…

The team of OrganoTherapeutics is proud to announce that we were successful in the Science4Life Venture Cup. This is a…

OrganoTherapeutics and InnoSer are joining forces to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership…